PAI-1 and Factor VII Activity Are Higher in IDDM Patients With Microalbuminuria

Microalbuminuria is associated with an increased risk of cardiovascular disease (CVD) in insulin-dependent diabetes mellitus (IDDM) patients, but the pathophysiological basis of this association is not clear. To see whether or not hemostatic dysfunctions might contribute to explain this association, we measured tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), factor VII activity, plasma fibrinogen, and plasma endothelin-1 (ET-1) in 13 microalbuminuric (albumin excretion rate [AER], 20–200 μg/min) and in 13 comparable normoalbuminuric (< 20 μg/min) IDDM patients. t-PA and ET-1 were similar in the two groups, whereas PAI-1 activity (5.65 ± 1.92 vs. 0.85 ± 0.58 IU/ml, P < 0.05), factor VII (87.85 ± 4.94 vs. 76.54 ± 2.31%, P < 0.05), and plasma fibrinogen (3.38 ± 0.21 vs. 2.65 ± 0.13 g/l, P < 0.05) were significantly higher in microalbuminuric than in normoalbuminuric patients. Plasma fibrinogen was related to AER (r² = 0.23, P < 0.05), whereas triglycerides and factor VII were related to PAI-1 (r² = 0.39, P < 0.001 and r² = 0.10, P < 0.05). These results suggest that microalbuminuria is associated with a hypercoagulative and hypofibrinolytic state. Hemostatic dysfunctions might be a pathogenetic link between microalbuminuria and CVD.